Jingchun Gao

Jingchun Gao

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Cancer Biology & Therapy
Verified
Journal Article
Open access
JGJingchun Gao
Jingchun Gao
ZZZhong Zheng
Zhong Zheng
BRBhupendra Rawal
Bhupendra Rawal
MSMichael Schell
Michael Schell
GBGerold Bepler
Gerold Bepler
EHEric Haura
Eric Haura
Minibrain-related kinase (Mirk) is a member of the dual specificity tyrosine- phosphorylation-regulated kinase (Dyrk)/minibrain family of dual-specificity protein kinases and is identical to Dyrk1B...

23 October 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YLYining Luo
Yining Luo
JGJingchun Gao
Jingchun Gao
XJXukai Jiang
Xukai Jiang
Ling ZhuLing Zhu
Ling Zhu
Qi ZhouQi Zhou
Qi Zhou
FZFanfan Zhou
Fanfan Zhou
Human proton-coupled oligopeptide transporters (PepTs) are important membrane influx transporters that facilitate the cellular uptake of many drugs including ACE inhibitors and antibiotics. PepTs mediate the absorption of di- and tri-peptides from dietary proteins or gastrointestinal secretions, facilitate the reabsorption of peptide-bound amino acids in the kidney, and regulate neuropeptide homeostasis in extracellular fluids. PepT1 and PepT2 have been the most intensively investigated of all PepT isoforms. Modulating the interactions of PepTs and their drug substrates could influence treatment outcomes and adverse effects with certain therapies. In recent studies, topology models and protein structures of PepTs have been developed. The aim of this review was to summarise the current knowledge regarding structure-interaction relationships (SIRs) of PepTs and their substrates as well as the potential applications of this information in therapeutic optimisation and drug development. Such information may provide insights into the efficacy of PepT drug substrates in patients, mechanisms of drug–drug/food interactions and the potential role of PepTs targeting in drug design and development strategies.